St Vincent’s Hospital Melbourne has signed a 12-month
supply agreement with New Zealand MedTech company Veriphi,
to deploy its breakthrough intravenous medication
verification technology in the hospital’s sterile oncology
compounding pharmacy.
The agreement marks the first
commercial hospital contract for Veriphi, which has spent
more than a decade developing an innovative analyser that
uses laser spectrometry, AI and cloud computing to verify
the identity and concentration of IV drugs in real time. The
goal: reduce preventable harm from medication errors and
improve dosing accuracy for vulnerable cancer
patients.
St Vincent’s Hospital Melbourne, a
tertiary public healthcare provider with more than 880 beds
and over 5,000 staff, is part of St Vincent’s Health
Australia – the country’s largest not for-profit health
and aged care provider.
“St Vincent’s Hospital
Melbourne is excited to be working with technology company
Veriphi to improve medication safety in our sterile oncology
compounding pharmacy,” said Andrew Cording, Chief
Pharmacist from St Vincent’s.
“The safety of our
patients, including medication safety, is a top priority for
St Vincent’s, so we are proud to be working with
world-leading technology.”
The agreement reflects a
shared commitment to innovation and safety in cancer care,
with Veriphi’s system designed to support pharmacists and
clinical staff in verifying complex, high-risk
medications.
“We are delighted to be
working with St Vincent’s Hospital Melbourne,” said Greg
Shanahan, Managing Director of Veriphi.Advertisement – scroll to continue reading
“Our values
regarding the protection of patient safety from medication
error align perfectly with St Vincent’s. We are proud to
collaborate with an organisation whose culture and focus on
patient outcomes are supported by Veriphi’s breakthrough
technology.”
Medication errors remain
one of the most serious – and preventable – threats to
patient safety worldwide. Intravenous drugs, particularly
those used in oncology, require precise handling and
verification to avoid harm. Veriphi’s analyser brings a
new layer of safety, enabling hospitals to verify each dose
at the point of compounding before administration to
patients.
The St Vincent’s partnership marks a major
milestone for Veriphi’s commercial rollout, with further
expansion plans underway across Australia, New Zealand, and
the United States.
Veriphi is currently raising funds
to expand its impact around the globe. New Zealand and
Australian residents can invest at
pledgeme.co.nz.
© Scoop Media
Discussion about this post